GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/Local Recurrence Risk After Horizontal Margin–Positive En Bloc Colorectal ESD

Local Recurrence Risk After Horizontal Margin–Positive En Bloc Colorectal ESD

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The systematic review and meta-analysis you are referencing provides an in-depth evaluation of the local recurrence risk after en bloc colorectal endoscopic submucosal dissection (ESD) with positive or indeterminate horizontal margins (HM1/x). Here is a detailed breakdown of the findings: ### Key Findings: 1.


The systematic review and meta-analysis you are referencing provides an in-depth evaluation of the local recurrence risk after en bloc colorectal endoscopic submucosal dissection (ESD) with positive or indeterminate horizontal margins (HM1/x). Here is a detailed breakdown of the findings:

### Key Findings:

1. **Pooled Recurrence Rate**:

  • Across 11 studies and 441 cases of HM1/x en bloc colorectal ESD, the pooled recurrence rate was found to be **4.3%**.
  • This indicates that while the recurrence risk is elevated compared to cases with negative horizontal margins (HM0), the absolute risk remains relatively low.

2. **Nature of Recurrences**:

  • Recurrence typically occurred at a **median of 14 months** post-procedure.
  • Among the histologically characterized recurrences, the majority (13 out of 16) were **benign (dysplasia)** rather than invasive cancer.
  • Invasive recurrences were associated with lesions initially classified as having invasive or high-grade dysplasia.

3. **Management of Recurrences**:

  • Most benign recurrences were successfully treated with **repeat endoscopic procedures**.
  • Invasive recurrences, however, required **surgical intervention**.

4. **Comparative Risk**:

  • The recurrence risk was significantly higher in HM1/x cases compared to HM0 cases, with a pooled odds ratio of **8.04**.
  • Despite this, the recurrence risk for noninvasive lesions was still relatively low, suggesting that the presence of HM1/x margins does not universally indicate a high recurrence risk.

5. **Implications for Surveillance**:

  • The findings suggest that current surveillance recommendations, which are largely based on data from piecemeal endoscopic mucosal resection, may be overly cautious for en bloc ESD cases with HM1/x margins.
  • Surveillance strategies could potentially be refined to balance early detection of recurrences with the avoidance of unnecessary interventions, especially for cases with low-risk pathology.

### Contextual Significance:

  • The study highlights the importance of distinguishing between benign and invasive recurrences when managing patients with HM1/x margins after en bloc ESD.
  • It also underscores the need for individualized surveillance protocols that take into account the specific pathology and recurrence risk of the lesion.

### Conclusion:

The local recurrence risk after en bloc colorectal ESD with positive or indeterminate horizontal margins (HM1/x) is low, at 4.3%, and is predominantly associated with benign dysplasia. Surveillance strategies may need to be adjusted to reflect this low absolute risk, especially for noninvasive lesions, while still ensuring the timely detection and management of any invasive recurrences.

Related Q&A

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer